HIMS near 52-week low as FDA issues 30 GLP-1 warning letters

Hims & Hers Health (NYSE: HIMS) fell sharply on Tuesday after the U.S. Food and Drug Administration issued 30 warning letters to telehealth companies over the illegal marketing of compounded GLP-1 weight-loss drugs, extending a regulatory offensive that has erased more than 75% of the company’s market value since its peak of $70.43 twelve months ago. The letters arrive less than four weeks after the FDA named Hims & Hers Health directly in a February 6 enforcement announcement that also triggered a Department of Justice referral by the Department of Health and Human Services. Tuesday’s selloff reversed a 13% gain from the prior session, illustrating the hair-trigger volatility that now characterises a stock trading near its 52-week low of $13.74 against a prior-year high of $70.43. The episode underscores a fundamental regulatory rerating of the compounded GLP-1 business model that Hims & Hers Health built into the centrepiece of its growth narrative.

Why did the FDA send 30 warning letters to GLP-1 telehealth companies in March 2026?

The March 3 warning letters target promotional language on company websites that implies compounded versions of semaglutide or tirzepatide are therapeutically equivalent to FDA-approved brand drugs such as Wegovy or Zepbound. Under the Federal Food, Drug, and Cosmetic Act, a compounded drug product cannot be marketed as a generic or equivalent substitute for an approved drug, and companies making such claims expose themselves to misbranding violations, seizure, injunction, or referral for criminal prosecution. Firms receiving letters have 15 business days to correct identified violations, a tight window that signals the FDA is not treating this as an introductory education exercise. The action follows a warning letter issued to Hims & Hers Health directly in September 2025, making Tuesday’s batch a deliberate escalation rather than the opening move in what is now a multi-front enforcement campaign.

The FDA’s posture under Commissioner Marty Makary has been notably more aggressive on compounded GLP-1s than prior administrations. The February 6 announcement stated the agency’s intent to restrict the active pharmaceutical ingredients used in non-approved compounded GLP-1 drugs at the source, meaning at the ingredient supply level rather than merely at the point of marketing. That distinction matters: restricting API access would shut down production capacity rather than merely require a label change, and it would affect the broader 503B outsourcing pharmacy sector, not just consumer-facing telehealth platforms.

How did the February 2026 Hims oral GLP-1 pill announcement trigger a regulatory and legal cascade?

The proximate cause of the current enforcement intensity was Hims & Hers Health’s February 5 announcement that it planned to offer a compounded oral semaglutide pill at $49 per month, marketed explicitly as containing the same active ingredient as Wegovy. The timing was pointed: Novo Nordisk had just received FDA approval in December 2025 for an oral form of semaglutide for obesity, the first pill of its kind, and early prescription volumes had been strong. By offering a compounded version at roughly one-third the list price of the lowest Wegovy oral dose, Hims & Hers Health was directly attacking the commercial ramp of a product Novo Nordisk had spent years and significant capital developing.

The FDA responded within 24 hours, naming Hims & Hers Health directly in its February 6 enforcement announcement, which was unusual and deliberate. The HHS General Counsel simultaneously announced the DOJ referral on social media. Novo Nordisk filed a patent infringement lawsuit two days later. Hims & Hers Health withdrew the oral GLP-1 product on February 7, stating the company had no oral pills shipped to patients, but the withdrawal did not extinguish the broader regulatory and legal exposure the company had created. The DOJ referral remains live, and Novo Nordisk’s lawsuit seeks to bar the company from compounding injectable semaglutide products as well.

What is the strategic and financial risk for Hims & Hers Health if compounded GLP-1 access is curtailed?

The GLP-1 weight-loss category became Hims & Hers Health’s fastest-growing segment after the company launched compounded injectable semaglutide in May 2024, exploiting a shortage period that gave 503B pharmacies legal room to produce compounded versions. The shortages have since ended, but Hims & Hers Health continued selling compounded semaglutide under a personalised-dosing argument that regulators are now directly contesting. In its full-year 2025 results, the company reported revenue of $2.35 billion, up 59% year-on-year, with the subscriber base reaching 2.5 million. Adjusted EBITDA reached $318 million, an 80% increase.

The financial question for investors is what percentage of that revenue and subscriber base is directly attributable to compounded GLP-1 prescriptions, and how much would survive a full prohibition on compounded semaglutide and tirzepatide. Chief Executive Andrew Dudum argued during the February 23 earnings call that the company has a durable weight-loss business even under a scenario where compounded GLP-1s are eliminated entirely, pointing to the company’s broader specialty portfolio and its 2026 revenue guidance of $2.7 billion to $2.9 billion. Investors have not been persuaded. The stock is down approximately 52% year-to-date, and the consensus analyst rating is Neutral, with a 12-month average price target of around $20, implying meaningful upside from current levels that analysts are reluctant to call with confidence given unresolved legal and regulatory variables.

The balance-sheet position provides some cushion. Net income for 2025 was approximately $128 million, and the company remains profitable at the operating level. But the growth premium embedded in the stock’s prior $70 valuation was built almost entirely on GLP-1 subscriber projections, and without those, the valuation arithmetic changes substantially. Deutsche Bank lowered its price target to $31 from $42 following the latest regulatory action, while Canaccord noted that legal risk may already be partially priced in.

How does the FDA crackdown affect the broader compounding pharmacy sector and patient access?

The impact of the FDA’s enforcement posture extends well beyond Hims & Hers Health. The Alliance for Pharmacy Compounding has publicly warned the FDA against over-correcting in a way that impedes legitimate 503A pharmacies, which produce individualised prescriptions for patients with specific clinical needs. The regulatory framework distinguishes between 503A pharmacies, which prepare small batches against individual prescriptions, and 503B outsourcing facilities, which mass-produce compounded drugs for broader distribution. The FDA’s API restriction proposal targets mass-marketed products and would primarily affect 503B operators and the telehealth platforms that distribute through them, but the line between personalised compounding and mass production is contested, and a broad enforcement posture could create collateral disruption for legitimate compounding operations.

For patients, the access question is material. The branded Wegovy oral pill carries a minimum out-of-pocket cost of $149 per month at the lowest dose, compared to the $49 price point Hims & Hers Health had proposed for its compounded version. A KFF survey from 2025 found that 27% of insured GLP-1 patients still paid full out-of-pocket costs, meaning the price differential is not theoretical for a significant patient cohort. If the FDA succeeds in restricting API access, that affordable alternative disappears, and patients either absorb the branded cost, access Novo Nordisk’s NovoCare direct pharmacy, or discontinue treatment.

What does this regulatory confrontation signal about the future of telehealth and compounding business models?

The Hims & Hers Health situation is a stress test for a broader class of telehealth companies that constructed revenue models around compounded versions of high-demand branded drugs. The model worked when the drugs were in shortage, and it persisted through legal grey zones when the shortages ended. What the current enforcement wave clarifies is that the FDA, under the current administration, is willing to use its full toolkit, including API restriction, DOJ referral, warning letters, and the threat of injunction and seizure, to challenge that model’s legitimacy when it believes mass marketing of non-approved drugs crosses a legal threshold.

For Hims & Hers Health, the next material development is how the DOJ referral proceeds and whether Novo Nordisk’s patent lawsuit advances to a stage where injunctive relief restricts existing injectable semaglutide sales, not merely the withdrawn oral product. For the broader sector, the FDA’s March 3 wave of 30 warning letters signals that the enforcement campaign is not targeted at one company but at a business model, and that companies across the telehealth and pharmacy compounding landscape face the same compliance and legal exposure that is currently repricing Hims & Hers Health’s equity.

Key takeaways: what the FDA GLP-1 compounding crackdown means for Hims & Hers Health, telehealth investors, and the pharma sector

• The FDA issued 30 warning letters on March 3, 2026, targeting telehealth companies that marketed compounded GLP-1 drugs as equivalents to FDA-approved therapies, marking an escalation from company-specific enforcement to sector-wide action.
• Hims & Hers Health (HIMS) is at the epicentre, trading near its 52-week low of $13.74 after losing more than 75% from its peak, with regulatory, legal, and DOJ exposure all unresolved.
• The February oral semaglutide product launch, which directly challenged Novo Nordisk’s newly approved Wegovy pill at less than a third of the price, triggered a disproportionately swift regulatory response and exposed the limits of the company’s compounding strategy.
• The FDA’s stated intent to restrict GLP-1 active pharmaceutical ingredients at source, rather than just at the marketing level, is the more significant long-term threat, potentially removing production capacity rather than merely requiring label corrections.
• A DOJ referral by the HHS General Counsel remains active, creating criminal exposure that goes beyond civil enforcement and represents an overhang that analyst price targets cannot yet adequately model.
• Novo Nordisk’s patent lawsuit targets injectable as well as oral compounded semaglutide, meaning even Hims & Hers Health’s existing core business is in scope, not only the withdrawn oral product.
• Management’s argument that the company has a durable weight-loss business without compounded GLP-1s is credible at the revenue level but has not yet been tested at the subscriber retention level, and the 2026 guidance range of $2.7 billion to $2.9 billion may embed assumptions about compounded GLP-1 continuity that the regulatory environment is actively eroding.
• The broader 503B outsourcing pharmacy sector faces comparable exposure, as the FDA’s enforcement language does not distinguish between Hims & Hers Health and other mass-marketing compounders.
• Patient access to affordable GLP-1 therapy is a political variable. Any evidence that the crackdown is pushing patients off medication at scale could generate congressional attention, creating a potential policy counterweight to pure enforcement.
• Analyst consensus is Neutral with an average 12-month target of approximately $20, suggesting the market has partially priced in the regulatory risk but has not resolved the binary outcomes around the DOJ referral and Novo Nordisk lawsuit.